Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) has received an average recommendation of "Moderate Buy" from the eighteen ratings firms that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, one has given a hold rating, twelve have given a buy rating and three have issued a strong buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $110.5455.
GPCR has been the subject of a number of analyst reports. Canaccord Genuity Group began coverage on shares of Structure Therapeutics in a research report on Monday, April 27th. They issued a "buy" rating and a $101.00 price objective for the company. Wall Street Zen upgraded Structure Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 1st. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Structure Therapeutics in a report on Friday, July 17th. Finally, HC Wainwright lowered their price target on Structure Therapeutics from $100.00 to $70.00 and set a "buy" rating on the stock in a research report on Thursday, June 11th.
Read Our Latest Report on GPCR
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP raised its position in Structure Therapeutics by 25.2% during the fourth quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company's stock worth $495,334,000 after acquiring an additional 1,432,797 shares during the period. Avoro Capital Advisors LLC lifted its stake in Structure Therapeutics by 21.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company's stock valued at $455,939,000 after buying an additional 1,150,000 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Structure Therapeutics by 5.2% in the 1st quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company's stock valued at $258,260,000 after buying an additional 264,833 shares in the last quarter. BVF Inc. IL boosted its holdings in Structure Therapeutics by 8.6% in the 4th quarter. BVF Inc. IL now owns 3,479,022 shares of the company's stock worth $241,966,000 after buying an additional 275,105 shares during the last quarter. Finally, Morgan Stanley increased its stake in Structure Therapeutics by 261.4% during the 4th quarter. Morgan Stanley now owns 2,087,834 shares of the company's stock worth $145,209,000 after buying an additional 1,510,093 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.
Structure Therapeutics Stock Performance
Shares of GPCR opened at $52.62 on Friday. The business's 50-day moving average is $47.36 and its two-hundred day moving average is $54.20. The company has a market capitalization of $3.74 billion, a P/E ratio of -60.48 and a beta of -1.43. Structure Therapeutics has a fifty-two week low of $15.85 and a fifty-two week high of $94.90.
Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). Analysts forecast that Structure Therapeutics will post -1.64 EPS for the current year.
About Structure Therapeutics
(
Get Free Report)
Structure Therapeutics NASDAQ: GPCR is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.
The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
